India, Nov. 18 -- Pharmaceutical powerhouse Bristol-Myers Squibb Company (BMY) today announced encouraging preliminary data from the open-label periods of the Phase 3 ADEPT trials evaluating KarXT in treating psychosis associated with Alzheimer's disease.

The data was presented at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference held at Boston, Massachusetts.

Psychosis affects about 30% to 50% of patients with Alzheimer's disease, often presenting as recurrent delusions and hallucinations. The psychosis increases risk of severe dementia, raises the likelihood of nursing home placement, injury, morbidity, or death.

KarXT (xanomeline and trospium chloride) is an investigational oral medication for various neurologic indica...